AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced the appointment of James Sapirstein, president and CEO, as chairman of the company’s board of directors, effective immediately. Sapirstein succeeds Edward J. Borkowski, who joined the AzurRx board in May 2015 and has served as chairman since April 2016. Borkowski will remain as lead independent director of the board of directors. “Having served on AzurRx’s board since 2015, I am committed to ensuring a prosperous future for the company,” said Borkowski. “Under James’ leadership, AzurRx has strategically expanded its existing pipeline to pursue new opportunities in the treatment of gastrointestinal conditions. The recent licensing agreement with First Wave Bio represents an exciting new chapter in the company’s growth with the potential to generate both near-term and long-range returns for AzurRx shareholders. James has been instrumental in implementing this strategy, and he is ideally suited to lead the company as both chairman and CEO as we seek to maximize the full potential of AzurRx’s pipeline and advance our clinical development programs.”
To view the full press release, visit https://ibn.fm/YPhf1
About AzurRx BioPharma Inc.
AzurRx BioPharma is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, FW-420, for grade 1 immune checkpoint inhibitor colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections. The company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. For more information, visit www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.